Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2023

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms

Résumé

Summary Myeloproliferative neoplasms in blastic phase (MPN‐BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN‐BP patients treated with a never‐before‐described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72–84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow‐up of 10.0 months (range 4.2–13.4), median overall survival was 13.4 months (95% CI 4.2–13.4). We did not detect any unexpected treatment‐related toxicity, and quality of life was improved.
Fichier principal
Vignette du fichier
Combination of azacitidine venetoclax and ruxolitinib in blast phase.pdf (535.64 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04237194 , version 1 (12-10-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Thomas Systchenko, Jean‐claude Chomel, Pilar Gallego-Hernanz, Niels Moya, Déborah Desmier, et al.. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms. British Journal of Haematology, 2023, 202 (2), pp.284-288. ⟨10.1111/bjh.18853⟩. ⟨hal-04237194⟩

Collections

UNIV-POITIERS
33 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More